Erectile Dysfunction Swells as Growth Market for Investors (PFE, MGRX, LLY, CELZ, HIMS, TEVA, BAYRY)

The erectile dysfunction market is expected to grow at a CAGR of 7.1% from 2021 to 2028. The growth of the market is attributed to the increasing prevalence of erectile dysfunction, rising awareness about the condition, and the availability of effective treatments.

Erectile dysfunction is a common condition that affects men of all ages. It is estimated that approximately 30% of men between the ages of 40 and 70 years old experience erectile dysfunction. The condition is caused by a variety of factors, including age, smoking, diabetes, heart disease, and obesity.

The increasing prevalence of erectile dysfunction is a major driver of the market. The global population is aging, and the number of men with erectile dysfunction is expected to increase as a result. Additionally, rising awareness about the condition is leading more men to seek treatment.

The availability of effective treatments is another major driver of the market. There are a number of FDA-approved medications available for the treatment of erectile dysfunction, including sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). These medications are effective in the majority of men, and they have a low risk of side effects.

The erectile dysfunction market is expected to continue to grow in the coming years. The increasing prevalence of the condition, rising awareness, and the availability of effective treatments are all expected to contribute to the growth of the market.

Additional factors that are expected to drive the growth of the erectile dysfunction market include the aging population, the rising prevalence of chronic diseases, the growing awareness of erectile dysfunction, and the development of new treatments.

The erectile dysfunction market is a large and growing market. The market is expected to continue to grow in the coming years due to a number of factors, including the increasing prevalence of the condition, rising awareness, and the availability of effective treatments.

With that in mind, we take a look below at some of the most interesting names in the ED space.


Pfizer Inc. (NYSE: PFE) is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide.

The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Pfizer Inc. (NYSE: PFE) recently reported financial results for the first quarter of 2023 and reaffirmed full-year 2023 financial guidance, including first-quarter 2023 revenues of $18.3 Billion, first-quarter 2023 diluted EPS of $0.97, a Year-Over-Year Decline of 29%, and Adjusted Diluted EPS(3) of $1.23, a Year-Over-Year Decline of 24%.

Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “This is an exciting time for Pfizer as we are already executing on and rigorously planning for an unprecedented number of anticipated new product and indication launches, most of which are expected to occur in the second half of 2023. We have made excellent progress toward this goal already this year with the U.S. approvals for Zavzpret, Cibinqo for adolescents and Prevnar 20 in pediatric patients, and regulatory filing acceptances for a Braftovi + Mektovi sNDA, sNDA for the Talzenna and Xtandi combination, elranatamab BLA and our RSV maternal vaccine candidate — which, if approved, would be the first vaccine for administration to pregnant individuals to help protect against the complications of RSV disease in infants from birth up to six months of age.”

Even in light of this news, PFE hasn’t really done much of anything over the past week, with shares logging no net movement over that period.

Pfizer Inc. (NYSE: PFE) managed to rope in revenues totaling $18.3B in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of -28.8%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities.


Mangoceuticals Inc (NASDAQ:MGRX) could very well be the most interesting name on this list. The stock is cheap, and it uses the same ED biotech as Cialis. But it has an interesting marketing angle. And, if you hold the tech constant between two companies, the better marketing angle generally wins.

However, because MGRX has been flying under the radar, it may have a whole lot of catching up to do.

Mangoceuticals Inc (NASDAQ:MGRX) announced this week the launch of its “Some Things Are Better Hard” digital marketing campaign. According to the company’s release, the Campaign leverages a new beautifully produced full-length video comprised of four individual video shorts, which will be widely distributed, together as a whole and separately, across multiple social media platforms, including, but not limited to, Facebook, Instagram, Snapchat, TikTok, YouTube, Google, and Twitter.

The composition is designed to reinforce the central theme that “Some Things Are Better Hard”, leveraging humor and an open and confident framing of the pursuit of male intimate health and personal improvement to defuse social taboos and normalize ED as a commonly shared functional obstacle to healthy male intimate experiences.

“This campaign is expected to help to further position Mango in the ED market as a uniquely accessible resource which has the goal of helping normal men achieve greater fulfillment and self-confidence while avoiding brand association with social discomfort,” stated MangoRx Co-Founder and CEO, Jacob Cohen. “We believe we have opened up a disruptive new lane in this rapidly growing $3.5 billion market. Peak performance is a good thing. Making your “intimate” life better is a good thing. Cultural barriers to talking frankly about that pursuit are a bad thing. Yet, until Mango came along, that’s typically how this marketplace tacitly operated. We believe that was a blind spot and the Mango brand is attempting to carve out a new model. We believe that the ‘Some Things Are Better Hard’ viral digital campaign is a perfect vehicle to press our incipient branding advantage.”

Mangoceuticals Inc (NASDAQ:MGRX) plans to continue to build its marketing arsenal to both educate and entertain its audience and target market customer base. The “Some Things Are Better Hard” digital ad campaign represents the Company’s second attempt to use creative marketing to widen the branding gap with its competitors and to be the first ED solution to successfully expand to include a younger demographic. The Company’s first commercial, which originally debuted on YouTube in November 2022, has already been viewed nearly 6 million times.

It’s a very slick ad. You can see it here.


Hims & Hers Health Inc (NYSE: HIMS) bills itself as the leading health and wellness platform on a mission to help the world feel great through the power of better health.

According to the company’s materials, “We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.”

Hims & Hers Health Inc (NYSE: HIMS) recently announced financial results for the first quarter ended March 31, 2023. “We are pleased with our outstanding performance in the first quarter, as our ability to deliver more personalized and accessible products and services is inspiring more customers to take better care of their health and well-being,” said Andrew Dudum, co-founder and CEO. “Our significant market opportunity, robust consumer demand and consistent execution across our four strategic pillars – trusted brand, leading technology, product innovation and clinical excellence – uniquely positions us as a trusted market leader.”

“Our resilient customer base and durable recurring revenue model is operating at a scale that enables us to generate high growth while generating incremental efficiencies,” said Yemi Okupe, CFO. “These dynamics enable us to unlock our market opportunity from a position of strength and we expect to continue delivering leading innovation and access to care to our customers to capitalize on our growth momentum while driving operational excellence.”

Even in light of this news, HIMS has had a rough past week of trading action, with shares sinking something like -10% in that time. That said, chart support is nearby, and we may be in the process of constructing a nice setup for some movement back the other way.

Hims & Hers Health Inc (NYSE: HIMS) managed to rope in revenues totaling $167.2M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 97.4%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels exceeding current liabilities ($179.6M against $47.9M).


Other key plays in the ED space include Eli Lilly And Co (NYSE: LLY), Creative Medical Technology Holdings Inc (NASDAQ: CELZ), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), and Bayer AG (OTCMKTS: BAYRY).

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at